

Non-Renounceable Entitlement Offer Results

24 April 2023: Osteopore Limited (ASX: OSX) (“**Osteopore**” or the “**Company**”) is pleased to advise that the non-renounceable pro-rata entitlement offer (**Entitlement Offer**) to raise up to approximately A\$2.63 million (before costs) closed on 17 April 2023 with strong support from eligible shareholders.

The Entitlement Offer gave eligible shareholders the opportunity to subscribe for one (1) fully paid ordinary share (**New Shares**) for every four (4) fully paid ordinary shares held (**Shares**) on the Record Date, at an issue price of A\$0.085 per New Share, with 1 free-attaching quoted option (**Quoted Option**) for every 1 New Share subscribed for.

The Entitlement Offer was strongly supported by eligible shareholders, who applied for 20,293,604 New Shares and 20,293,604 Quoted Options, raising approximately \$1,725,000 (before costs), pursuant to their entitlements. This represents an approximate 70% take up rate of entitlements by eligible shareholders.

The Company (in consultation with Cadmon Advisory Pty Ltd (**Lead Manager**)) has the right to now place the shortfall of 10,690,447 New Shares and 10,690,447 Quoted Options (**Remaining Shortfall Securities**) to new investors by no later than 17 July 2023 (**Shortfall Offer**). In accordance with the terms of the Shortfall Offer, the Remaining Shortfall Securities will be allocated at the discretion of the Company (in consultation with the Lead Manager).

The New Shares and Quoted Options applied for under the Entitlement Offer will be issued on 24 April 2023, with normal trading of the New Shares and Quoted Options expected to commence on 26 April 2023.

The Company thanks participating shareholders for their ongoing support.

This announcement has been approved for release by the Board of Osteopore.

For more information, please contact:

Mark Leong

Executive Chairman

Osteopore Limited

+65 9011 7009

Mark_Leong@osteopore.com

About Osteopore Limited

Osteopore Ltd is an Australia and Singapore based medical technology company commercialising a range of products specifically engineered to facilitate natural bone healing

across multiple therapeutic areas. Osteopore's patented technology fabricates specific micro-structured scaffolds for bone regeneration through 3D printing and bioresorbable material.

Osteopore's patent-protected scaffolds are manufactured using a proprietary manufacturing technique with a polymer that naturally dissolve over time to leave only natural, healthy bone tissue, significantly reducing post-surgery complications commonly associated with permanent bone implants. Our 3D printer technology is not available in the market and unique to Osteopore.